Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GIGI QIQI CHEN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1821073636
CMS profile
82179
Location
PLEASANT HILL, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$17,260.57

136 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GIGI QIQI CHEN

NPI 1821073636 · CMS profile ID 82179

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PLEASANT HILL, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821073636?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GIGI QIQI CHEN, NPI 1821073636, CMS profile ID 82179. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821073636?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GIGI QIQI CHEN, NPI 1821073636, CMS profile ID 82179. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821073636?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GIGI QIQI CHEN, NPI 1821073636, CMS profile ID 82179, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1821073636?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

136 matching records · $17,260.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 136 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–136 of 136.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $24.8804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229083220 CMS
PFIZER INC. $36.7504/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229063872 CMS
Merck Sharp & Dohme LLC $22.9104/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238091711 CMS
E.R. Squibb & Sons, L.L.C. $21.0103/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184939081 CMS
Novartis Pharmaceuticals Corporation $28.6203/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200069684 CMS
SERVIER PHARMACEUTICALS LLC $24.7703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229098029 CMS
Daiichi Sankyo Inc. $26.0403/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197055287 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.1303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225493266 CMS
Gilead Sciences, Inc. $17.8603/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234550203 CMS
Deciphera Pharmaceuticals Inc. $18.8503/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235958551 CMS
Exelixis Inc. $30.2903/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218794545 CMS
Daiichi Sankyo Inc. $21.7203/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197055209 CMS
Celgene Corporation $28.8103/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184939063 CMS
Bayer Healthcare Pharmaceuticals Inc. $25.4203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225493260 CMS
ABBVIE INC. $20.0003/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201643021 CMS
AstraZeneca Pharmaceuticals LP $21.8502/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206649432 CMS
SpringWorks Therapeutics, Inc. $27.6802/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232161151 CMS
PFIZER INC. $30.5002/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228985624 CMS
Merck Sharp & Dohme LLC $24.5002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238270572 CMS
GENZYME CORPORATION $24.4002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233361420 CMS
Janssen Biotech, Inc. $25.7102/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174746132 CMS
AstraZeneca Pharmaceuticals LP $28.1801/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206356716 CMS
Daiichi Sankyo Inc. $0.9501/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197074329 CMS
PFIZER INC. $1,620.0001/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1230498301 CMS
Aadi Bioscience, Inc. $18.3801/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250852805 CMS
PFIZER INC. $24.9201/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228950539 CMS
PFIZER INC. $0.1401/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228972505 CMS
PFIZER INC. $18.1801/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229197717 CMS
E.R. Squibb & Sons, L.L.C. $1,437.5001/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184939049 CMS
Merck Sharp & Dohme LLC $28.6401/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238180235 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.5301/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223861946 CMS
E.R. Squibb & Sons, L.L.C. $21.1001/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184939047 CMS
Deciphera Pharmaceuticals Inc. $18.8801/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235958549 CMS
Janssen Biotech, Inc. $25.6801/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174746001 CMS
Janssen Biotech, Inc. $0.1101/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174746150 CMS
Alnylam Pharmaceuticals Inc. $19.4401/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212773309 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28,339.09 113
PY2020 $10,003.50 54
PY2021 $8,424.46 52
PY2022 $22,138.75 61
PY2023 $13,653.99 130
PY2024 $6,492.66 61
PY2025 $17,260.57 136

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $112,190.25 42
PY2024 Principal investigator $68,208.10 36
PY2023 Principal investigator $79,406.58 47
PY2022 Principal investigator $90,725.40 29
PY2021 Principal investigator $40,548.65 38
PY2020 Principal investigator $51,069.25 42
PY2019 Principal investigator $67,707.18 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $7,374.00 12/22/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175437531
Principal investigator 1 BioNTech SE $500.00 12/11/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT122 No dispute reported 06/30/2026 1249021106
Principal investigator 1 Janssen Research & Development, LLC $2,793.61 12/08/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175437535
Principal investigator 1 Janssen Research & Development, LLC $7,698.90 12/08/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175437553
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,642.10 11/19/2025 Non-covered Recipient Entity
John Muir Health Cancer Medical Group
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235996473
Principal investigator 1 BioNTech SE $330.00 11/01/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT327 No dispute reported 06/30/2026 1249021108
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT327 No dispute reported 06/30/2026 1249021110
Principal investigator 1 BioNTech SE $85.00 11/01/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT327 No dispute reported 06/30/2026 1249021112
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT327 No dispute reported 06/30/2026 1249021114
Principal investigator 1 Incyte Corporation $277.20 10/30/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240475813
Principal investigator 1 Incyte Corporation $1,000.00 10/23/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240475808
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/20/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175437511
Principal investigator 1 Janssen Research & Development, LLC $750.00 10/17/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175437561
Principal investigator 1 Janssen Research & Development, LLC $1,261.00 10/02/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175437486
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $88.99 09/30/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Concord
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) No dispute reported 06/30/2026 1236000944
Principal investigator 1 Janssen Research & Development, LLC $3,960.00 09/01/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437508
Principal investigator 1 BioNTech SE $1,000.00 08/21/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249021023
Principal investigator 1 Janssen Research & Development, LLC $98.67 07/25/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437567
Principal investigator 1 BioNTech SE $280.00 07/22/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249021021
Principal investigator 1 Janssen Research & Development, LLC $4,524.00 07/22/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437541
Principal investigator 1 Janssen Research & Development, LLC $4,286.00 07/01/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437574
Principal investigator 1 Incyte Corporation $250.00 06/24/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240475805
Principal investigator 1 BioNTech SE $1,400.00 06/19/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249020991
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/16/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437502
Principal investigator 1 Janssen Research & Development, LLC $824.00 06/16/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437518
Principal investigator 1 Janssen Research & Development, LLC $38.33 06/16/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437586
Principal investigator 1 Janssen Research & Development, LLC $3,544.00 06/02/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437494
Principal investigator 1 BioNTech SE $1,000.00 05/27/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249021001
Principal investigator 1 BioNTech SE $1,400.00 05/22/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249020987
Principal investigator 1 Incyte Corporation $277.20 05/08/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240475800
Principal investigator 1 BioNTech SE $202.00 05/02/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249020997
Principal investigator 1 Incyte Corporation $750.00 04/03/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240475795
Principal investigator 1 Hoffmann-La Roche Limited $4,941.05 03/27/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1211546123
Principal investigator 1 BioNTech SE $3.00 03/25/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249020971
Principal investigator 1 BioNTech SE $500.00 03/25/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
BNT-122-01 No dispute reported 06/30/2026 1249020973
Principal investigator 1 BeiGene, Ltd. $1,000.00 03/17/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320356
Principal investigator 1 BeiGene, Ltd. $1,500.00 03/17/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320358
Principal investigator 1 Janssen Research & Development, LLC $26,000.00 03/10/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437523
Principal investigator 1 Janssen Research & Development, LLC $10,250.00 03/10/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437548
Principal investigator 1 Janssen Research & Development, LLC $6,400.00 03/10/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437580
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 03/10/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175437593
Principal investigator 1 Incyte Corporation $277.20 02/20/2025 Covered Recipient Teaching Hospital
John Muir Medical Center - Wc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240475816